JAVIER
PUENTE VÁZQUEZ
Profesor asociado
Institute of Oncology Ljubljana
Liubliana, EsloveniaPublicacións en colaboración con investigadores/as de Institute of Oncology Ljubljana (3)
2024
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45